93 related articles for article (PubMed ID: 2308979)
1. Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.
Tong AW; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Prog Clin Biol Res; 1990; 333():155-64. PubMed ID: 2308979
[TBL] [Abstract][Full Text] [Related]
2. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
Tong AW; Lee J; Wang RM; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Cancer Res; 1989 Sep; 49(17):4829-34. PubMed ID: 2569359
[TBL] [Abstract][Full Text] [Related]
3. Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complement.
Stone MJ; Tong AW; Fay JW; Lee JC
Cancer Detect Prev; 1988; 12(1-6):621-35. PubMed ID: 3180147
[TBL] [Abstract][Full Text] [Related]
4. Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement.
Kulkarni SS; Wang ZM; Spitzer G; Taha M; Hamada H; Tsuruo T; Dicke KA
Blood; 1989 Nov; 74(6):2244-51. PubMed ID: 2572283
[TBL] [Abstract][Full Text] [Related]
5. Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement.
Tong AW; Lee JC; Fay JW; Stone MJ
Blood; 1987 Nov; 70(5):1482-9. PubMed ID: 3663943
[TBL] [Abstract][Full Text] [Related]
6. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
7. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Bast RC; De Fabritiis P; Lipton J; Gelber R; Maver C; Nadler L; Sallan S; Ritz J
Cancer Res; 1985 Feb; 45(2):499-503. PubMed ID: 3967224
[TBL] [Abstract][Full Text] [Related]
8. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
[TBL] [Abstract][Full Text] [Related]
9. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens.
Futscher BW; Blake LL; Gerlach JH; Grogan TM; Dalton WS
Anal Biochem; 1993 Sep; 213(2):414-21. PubMed ID: 8238918
[TBL] [Abstract][Full Text] [Related]
10. Elimination of malignant clonogenic cells from human bone marrow using multiple myeloid cell-specific monoclonal antibodies and complement.
Hu ZB; Yu ZF; Qiao CN; Ma WL
Chin Med J (Engl); 1991 Aug; 104(8):664-8. PubMed ID: 1914634
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Uckun FM; Ramakrishnan S; Houston LL
J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of immunoconjugates consisting of doxorubicin linked to complement-fixing monoclonal antibody DLC-48 for bone marrow purging of B-cell lymphomas.
Winter JN; Bass B; Bringman T; Nedwin G
Prog Clin Biol Res; 1990; 333():171-83. PubMed ID: 2408059
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion of complement by an automated cell processor enhances cytotoxicity of monoclonal antibody sensitized leukemia cells.
Howell AL; Fogg-Leach M; Davis BH; Ball ED
Bone Marrow Transplant; 1989 May; 4(3):317-22. PubMed ID: 2659117
[TBL] [Abstract][Full Text] [Related]
14. Low antigen density leukemia cells: selection and comparative resistance to antibody-mediated marrow purging.
Janssen WE; Lee C; Gross S; Gee AP
Exp Hematol; 1989 Mar; 17(3):252-7. PubMed ID: 2917623
[TBL] [Abstract][Full Text] [Related]
15. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
[TBL] [Abstract][Full Text] [Related]
16. Distribution of the 124-kd antigen defined by monoclonal antibody AML-1-99 on normal and leukemic myeloid cells.
Howell AL; Miller R; Keefe KA; McIntyre OR; Stockner M; Sullivan R; Hibbert SR; Noelle RJ; Ball ED
Exp Hematol; 1988 Mar; 16(3):176-83. PubMed ID: 3422192
[TBL] [Abstract][Full Text] [Related]
17. T-cell depletion of Cercopithecus aethiops monkey bone marrow with Campath-1 monoclonal antibody and complement.
Phan DT; Barta E; Gidáli J; Fehér I; Harsányi V; Petrányi GG; Hollán SR
Haematologia (Budap); 1987; 20(3):155-63. PubMed ID: 3500899
[TBL] [Abstract][Full Text] [Related]
18. Anti-neuroblastoma monoclonal antibodies which do not bind to bone marrow cells.
Frantz CN; Duerst RE; Ryan DH; Gelsomino NL; Constine LS; Gregory PK
Prog Clin Biol Res; 1985; 175():485-99. PubMed ID: 3887430
[TBL] [Abstract][Full Text] [Related]
19. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
20. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
